Fig. 3.

Nephrotoxicity of lesinurad in placebo-controlled Phase 3 RCTs with 6 (monotherapy: M) or 12 months of follow-up (associated with XO inhibitors: CLEAR1, CLEAR 2, CRYSTAL). The 400-mg dose (red) is not indicated in routine clinical practice because of nephrotoxicity risk. (A, B) Change in ECC according to lesinurad dose in Phase 3 RCTs, CLEAR1 and CLEAR2. In both RCTs lesinurad was used together with allopurinol. Change in ECC (mL/min) in CLEAR 2 from baseline to last follow-up on drug. (C–E) Incidence of nephrotoxicity as defined by different thresholds of fold change in sCr for patients with any baseline eGFR. (F–H) Incidence of nephrotoxicity defined as an increase in sCr for patients at different baseline eGFR categories in patients treated with XO inhibitors. Data obtained from [30, 33, 40]. M stands for lesinurad monotherapy.